Wearables aiding illness
Fitness trackers are proving valuable for people with chronic conditions like long Covid and POTS — users report real‑time pacing and symptom tracking, and some clinicians are starting to use ECG‑capable wearables for longer rhythm monitoring in consultations My fitness tracker is a secret weapon against my chronic illness | The Verge Fitness trackers are useful but not always reliable. The broader market is growing fast — wearable sensors are forecast to reach about $13.2B by 2034 as devices tie into smartphones and IoT for continuous health data Wearable Sensors Market Size to Reach $13.2 Billion Worldwide by 2034 with 21.4% CAGR - Newstrail.
Scripps Research (scripps.edu) a remote trial on March 11, 2024 testing wrist-worn activity trackers plus educational pacing materials in people with long COVID, aiming to measure symptom changes without in-person visits. A Netherlands preprint (March 18, 2025) continuously recorded heart rate variability in 127 people with long COVID and 21 controls and found lower HRV in patients that stayed suppressed for 24 hours after exercise (p=0.010), linking autonomic dysfunction to post‑exertional malaise. (medrxiv.org) Mayo Clinic registered an observational study to test a wearable biosensor and mobile platform for remotely building diagnostic physiological profiles in suspected POTS patients, enrolling adults planned for confirmatory testing in its POTS Innovation program. (mayo.edu) The WEAR‑TECH cohort compared Apple Watch Series 6 single‑lead ECGs against simultaneous 12‑lead ECGs using 400 paired recordings and reported clinical agreement rates of 21% for <10ms differences, 45% for <20ms, and 71% for <40ms across intervals. (academic.oup.com) The American College of Cardiology issued a clinician tool on May 20, 2025 outlining when to incorporate Apple Watch heart features into care and noting several FDA‑authorized functions for adults 22+, while its guidance also cautions that watches are inappropriate where immediate clinician alerts are required. (acc.org) The ACC document also cites validation data showing the Irregular Rhythm Notification had an 88% sensitivity compared with a continuously monitoring ECG patch. (acc.org) Population and clinician data show rising adoption but mixed clinical integration: a national survey found wearable use rose to about 36.4% of U.S. adults in 2022, (jmir.org) while a recent physician survey lists time, limited reimbursement, and workflow concerns as the main barriers to using smartwatch cardiovascular data in practice. (sciencedirect.com)
